Search
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigationalhas a higher affinity towards CD20. … [A6921] Ofatumumab was first approved by the FDA in 2009.
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigational[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. … [L33204] Isoprenaline was granted FDA approval on 19 February 1948.[L33155]
Categories: Compounds used in a research, industrial, or household settingElamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigationalFood and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. … [A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane.
Brilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]
Categories: Compounds used in a research, industrial, or household settingSYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Synonyms: (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrile, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileMarstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigationalMarstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalIt is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period. … Norelgestromin is a progestin used as the progestational component of combined hormonal contraceptives.
Synonyms: D-Norgestrel 3-oximeKappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].